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Power morcellation of surgical specimen during laparoscopic surgery is a practical 
 technology that provides the opportunity to perform several minimally invasive proce-
dures. However, this technology brought forward additional risks and complications 
associated with dissemination of both benign and malignant tissues inside the abdom-
inal cavity. Based on startling cases, Food and Drug Administration (FDA) announced a 
discouraging statement on the use of power morcellators that decreased the number 
of minimally invasive approaches in the following period. As a response to these con-
cerns and negative impacts of the FDA statement, researchers developed several new 
approaches resulting in contained or in-bag morcellation methods. In this review, we 
aimed to discuss these current methods and provide an insight for future developments.
Keywords: contained morcellation, enclosed morcellation, in-bag morcellation, laparoscopy, hysterectomy, 
myomectomy
inTRODUCTiOn
Minimally invasive surgery (MIS) has dramatically changed the vision of modern surgical approach. 
Advantages of MIS in the treatment of a diverse range of gynecological conditions have been well 
demonstrated by several studies in the last few decades. These well-documented advantages include 
less perioperative complications, better cosmetic results, faster recovery, and improved quality of life 
compared to laparotomy (1). In the United States, according to the recent reports, almost half of the 
annual hysterectomy procedures for benign gynecologic indications were performed via MIS (2). In 
addition, thousands of women underwent myomectomy and benefited from the virtues of advanced 
minimally invasive methods in the last few decades.
Minimally invasive surgery techniques involve vaginal, laparoscopic (conventional multiport or 
single site), and robotic surgical approaches. Their advantages over open surgeries in the treatment of 
a wide range of gynecologic diseases have been acknowledged. As a consequence, American College 
of Obstetricians and Gynecologists and American Association of Gynecologic Laparoscopists 
recommended the use of vaginal or laparoscopic approaches in hysterectomy for the treatment of 
benign gynecologic diseases (3, 4).
Along with the significant technological advances and expanded application fields, MIS brought 
an inherent challenge, the safe extraction of surgical specimen, which is also the primary focus of this 
review. Developed surgical techniques improved our capabilities and also brought serious risks and 
legal litigations. In the following sections, we have discussed our current knowledge of morcellation 
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methods, their potential risks, and promising solutions as future 
directions.
TiSSUe MORCeLLATiOn AnD  
POTenTiAL RiSKS
From past to the present, MIS techniques rapidly advanced along 
with innovative solutions developed when surgeons confronted 
by obstacles. At the time of the uterine specimen (uterine fibroid 
or uterus itself) removal from the abdominal cavity, the surgi-
cal specimen is frequently too large to be extracted through the 
routes used to access the surgical field without impairing the 
tissue integrity. To accomplish the operation overcoming this 
challenge, an additional process named morcellation has been 
described. Morcellation procedure can be defined as fragmenta-
tion of the large tissue specimen into smaller pieces to facilitate 
the specimen extraction (5). This procedure can be performed 
either manually using a surgical scalpel or by using a specifically 
designed electromechanical device.
Power morcellation (PM), also known as electromechani-
cal morcellation, has been introduced to the modern surgical 
practice in 1993 and utilized in various specialties including 
gynecology, general surgery, and urology after the approval of 
the US Food and Drug Administration (FDA) in 1995 (6, 7). 
Power morcellators are specifically designed to transform electri-
cal energy into mechanical power, which is needed for cutting 
the surgical specimen into smaller pieces to be easily removed 
through a 12–20  mm laparoscopic access port. Since its first 
application, various types of power morcellator with different 
features in design, weight, working principle, blade size, and 
cutting speed have been developed (8). Currently, there are 11 
different commercially available devices some of which have been 
reported to have higher rates of morcellation performance (7). 
However, there is lack of evidence demonstrating that any one 
of the devices is associated with higher risks of organ injuries or 
tissue dissemination.
Severe complications mostly involved bowels and vascular 
structures caused by the spinning blade of the morcellator were 
reported (9). Also, performing intracorporeal PM can lead scat-
tering of benign tissues such as leiomyoma and endometriosis. 
Dispersed tissue fragments may implant on abdominal organ 
surfaces leading to inflammation, infection, and intestinal 
obstruction, which require additional surgical interventions 
and treatments (10–12). However, among the concerns the most 
formidable one that brought this technology under scrutiny is 
unintentional dissemination of malignant cells, which can lead 
severe consequences such as worsening the prognosis by upstag-
ing the occult cancer. Recently, iatrogenic dissemination of 
unexpected malignancies such as sarcomas and adenocarcinomas 
after intracorporeal morcellation has been reported and draw the 
attention of popular media around this surgical method (13–15). 
After two decades of surgical practice with power morcellators, 
FDA released a warning statement discouraging the use of PM in 
women undergoing hysterectomy and myomectomy based on the 
safety concerns (16).
Uterine cancers are the most common gynecologic malignan-
cies in the United States with an estimation of more than 10,000 
deaths in 2016 (17). Endometrial cancers are usually diagnosed 
in women at older ages and are uncommon in reproductive ages. 
They are typically identified by abnormal bleeding and can be 
diagnosed with an appropriate preoperative evaluation using 
imaging and endometrial sampling. However, uterine sarcomas 
are very rare with an incidence of 7–8% of all uterine cancers and 
there is no currently available method for an accurate preopera-
tive diagnosis (18). Although the occurrence of uterine sarcomas 
is very rare in women younger than 40 years, its risk factors are 
not well understood. They are usually discovered postoperatively 
and, regardless of the tumor stage, the prognosis is very poor with 
only 40–66% survival at 5 years (19, 20).
The risk of unanticipated uterine sarcoma in patients undergo-
ing a uterine morcellation was 0.22% in a retrospective cohort 
study (21). Recently, Wright et  al. investigated the prevalence 
of underlying uterine malignancies in women who underwent 
myomectomy in a large nationwide retrospective study, which 
included more than 40,000 patients from 496 hospitals. The 
prevalence of uterine cancer in women who underwent myomec-
tomy with and without PM during surgery was 0.09 and 0.18%, 
respectively (22). Although the overall risk of occult malignancy 
appears to be very low, PM should be used with caution in older 
patients, as the risk significantly increases with age.
In patients with suspicion for occult uterine malignancy after 
preoperative evaluation, alternatives to morcellation should be 
recommended. In these cases, minilaparotomy or vaginal extir-
pation of the uterine specimen is more reliable option for tissue 
extraction as the patient safety is the main priority. Moreover, it 
should be emphasized that there is no currently available method 
for tissue extraction that completely eliminates the risk of cellular 
dissemination.
COnTAineD TiSSUe eXTRACTiOn
In an Italian survey, Mandato et  al. reported that 58.7% of 
gynecologists declared that they would change their surgical 
practice after FDA safety communication only to prevent legal 
litigation (23). In another recent study from US, comparing the 
number of cases performed during 8  months before and after 
FDA warning statement, authors reported 5.8 and 19% decrease 
in the number of minimally invasive hysterectomy and myomec-
tomy procedures, respectively (24). More concerning, Harris 
et al. reported that the number of major surgical complications 
and hospital readmissions were significantly increased with the 
decreasing numbers of minimally invasive hysterectomy. These 
results, from a statewide surgical cohort study, can be translated 
to an additional $23 million burden to annual health care costs 
(25). In response to these negative impacts on surgical outcomes 
and health care costs, surgeons embarked on a quest to overcome 
the challenges and eliminate tissue dissemination during morcel-
lation (26–44).
Abdominal Approach to Contained  
Tissue extraction
In 2014, Einarsson et al. described “Sydney in bag morcellation 
technique” as a contained abdominal morcellation method for 
multiport laparoscopic surgery (26). In this technique, using 
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two different tissue retrieval systems—a 15-mm EndoCatch bag 
(Covidien, Mansfield, MA, USA) and Anchor TRS-200 tissue 
retrieval system (Anchor Surgical, Addison, IL, USA)—authors 
placed the surgical specimen inside the retrieval bag and inserted 
a 12-mm trocar into the bag through the umbilicus followed by 
insufflation. Subsequently, a 5-mm balloon-tip Kii trocar (Applied 
Medical, Rancho Santa Margarita, CA, USA) pierced into the 
insufflated bag with the specimen inside. Power morcellator was 
introduced through the umbilicus incision and morcellation 
performed under optic visualization. Once morcellation has been 
completed, the isolation bag was removed through the umbilical 
port after deflation of trocar balloon.
The Sydney in-bag morcellation technique presents a novel 
approach for contained PM. However, it poses a potential risk 
of tissue dissemination arising from the piercing of the isolation 
bag. Penetrating the bag inside the abdominal cavity jeopardizes 
the bag integrity and may result in tissue leakage. Therefore, we 
developed an innovative method for enclosed morcellation using 
a surgical glove (27). Inspired by the topological shape of the sur-
gical glove, we aimed to create an isolated space with protrusions 
that can be manipulated through the ports on abdominal wall. 
In our technique, fingertips of the surgical glove were exterior-
ized through the trocars that enabled direct access to the isolated 
space without disrupting the surface integrity of the containment. 
However, our technique was limited with the volume and elastic-
ity of the surgical glove, as it is not specifically designed for this 
purpose. Inspiring from this method, Rimbach et al. developed 
a novel isolation bag (More-Cell-Safe, A.M.I., Austria) with two 
openings and successfully applied it in laparoscopic PM of the 
uterus. The larger opening was used for placement of the uterine 
tissue inside the bag and introduction of the power morcellator 
as well, while the smaller opening was used to insert the laparo-
scope (28). Recently, Paul et al. described the use of a specially 
designed isolation bag using a similar bag shape (MorSafe; Veol 
Technologies, Mumbai, India) for two-port morcellation method 
(29).
Morcellation of uterine specimen within an insufflated isola-
tion bag during single-site laparoscopic surgery was also recently 
described. Using a cordless electric morcellator, the LiNA Xcise 
(LiNA Medical, Glostrup, Denmark), introduced through a 
5-mm trocar, uterine specimens of 12 patients were morcellated 
in a contained fashion without any complications (30). As it 
requires neither bag penetration nor piercing with trocar, this 
technique appears as a reliable approach.
Contained PM of uterine specimen in multiport laparoscopy 
was associated with 20–26 min longer operative time when com-
pared with those without PM (31, 32). However, no significant 
differences related to estimated blood loss, length of hospital stay, 
and perioperative complications were recorded. On the other 
hand, Venturella et al. reported operative times similar to in-bag 
manual morcellation without PM (33). These reported variations 
in operative times are possibly due to the differences in morcel-
lation technique, tissue size, and surgical experience. The current 
body of evidence suggests that contained PM is a time efficient 
and feasible method in laparoscopic surgery.
To evaluate the safety of contained PM in terms of tissue 
dissemination, Cohen et al. conducted both in vivo and in vitro 
studies (34, 35). Although investigators detected dye leakages in 
a few trials, PM in an isolation bag was suggested as a feasible 
method with the need of further studies to confirm the safety of 
current techniques and materials.
vaginal Approach to Contained Tissue 
extraction
Vaginal channel is a natural orifice through which an abdominal 
specimen can be easily removed after creation of colpotomy or 
culdotomy incision. Vaginal route can provide removal of entire 
uterus without morcellation especially in oncological cases. 
However, in cases with severe vaginal atrophy, narrow pelvic 
arch, nulliparity, and bulky uterus, the tissue removal can be 
challenging. When uterine specimen is too large to be extracted, 
intact morcellation can be performed through vagina. Vaginal 
morcellation is relatively faster and simple to learn and perform. 
Commonly used vaginal morcellation techniques include 
bivalving, wedge resection, coring, myomectomy, and recently 
described paper roll method (36, 37). Moreover, vaginal morcel-
lation can be performed within a containment bag to prevent 
tissue dissemination. After either abdominal or vaginal inser-
tion of containment bag in various types, authors accomplished 
vaginal morcellation in an enclosed fashion (38–41). Also, 
vaginal retractors can be used to facilitate extraction providing 
better exposure.
Besides its efficiency, vaginal tissue extraction should be 
performed in experienced hands as it carries the risks of blad-
der, rectum, and vaginal lacerations (38). Therefore, meticulous 
inspection of the surgical field should be done to exclude pos-
sible injuries after removal of the specimen. Although contained 
vaginal morcellation may prevent the risk of tissue dissemina-
tion, Solima et al. reported that in 4 of 12 cases, the containment 
bags were found to be ruptured after filling up with methylene 
dye (42). Demonstrating potential risk of tissue dissemination 
even in contained vaginal morcellation, authors addressed the 
importance of development of new, resistant, and durable materi-
als and devices.
SUMMARY AnD FUTURe DiReCTiOnS
Morcellation of the large surgical specimen is a crucial step 
in the accomplishment of minimally invasive procedures 
and utilization of power morcellator facilitates this frequent 
time-consuming process. However, it should be noted that 
performing uncontained intracorporeal morcellation of 
uterine specimen either via vaginal or abdominal approach 
has been associated with tissue dissemination (43). After PM 
in laparoscopic myomectomy, Toubia et  al. detected spindle 
cells in post-morcellation peritoneal washing samples (44). 
Therefore, morcellation of the specimen in an enclosed fashion 
should be the preferred method as many developed techniques 
and several specimen retrieval bags for this method have been 
widely available. Nonetheless, in patients with suspicion for 
occult uterine malignancy after an appropriate preoperative 
evaluation, morcellation should be avoided (45). In those cases, 
alternatives such as minilaparotomy or vaginal retrieval of the 
uterine specimen are more reliable options.
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Vaginal extraction of surgical specimen in a containment 
bag is a feasible option, besides it still carries the risk of adjacent 
pelvic organ injuries and bag rupture. Although it has not been 
described yet, vaginal PM of uterine specimen can be a hypo-
thetical solution to overcome these limitations. We believe, by 
modifying our previously described method, this hypothetical 
approach can be actualized in experienced hands. However, 
larger bags made with resistant and elastic materials are needed 
to realize this method.
As the main concern with morcellation is the spillage of malig-
nant cells, it should be realized that cellular dissemination is most 
likely initialized by the surgical procedure itself. Spindle cells after 
myomectomy have been detected in peritoneal washings even in 
the absence of the morcellation (27, 35, 44). Although its clinical 
significance is still unclear, patients should be informed that there 
is an inherent risk of cellular dissemination during myomectomy 
procedure regardless of morcellation. In this point, we believe 
that an advanced innovative surgical method providing an 
enclosed space not only for the morcellation procedure but also 
for the preceding myomectomy procedure can be developed in 
the future. This futuristic view may provide an insight for the 
future developments of new surgical methods and devices.
In conclusion, it should be emphasized that there is currently 
no available method for tissue extraction that completely elimi-
nates the risk of cellular dissemination. Therefore, further inves-
tigations and technological developments are needed to improve 
morcellation technique. Collaboration between surgeons, device 
manufacturers, and designers should also be encouraged to find 
innovative solutions.
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